Humacyte prices 25M-share public offering at $2.00/share, expects $50M gross proceeds

Humacyte, Inc.

Offering of 25,000,000 shares at $2.00/share; gross proceeds ~$50M, net ~$46.6M after discounts and expenses.
Underwriters have 30-day option to purchase up to an additional 3,750,000 shares at the same price.
Proceeds to fund SYMVESS commercialization in vascular trauma, pipeline development, and working capital.
Expected to close on March 27, 2025; TD Cowen, Barclays, and BTIG are joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.